TD Cowen issued a buy rating and price target for Edwards Lifesciences, while Royal Bank of Canada reiterated its 'outperform' rating on the stock.
1 report, 1 independent
Updated Jun 16
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen issued a buy rating and price target for Edwards Lifesciences, while Royal Bank of Canada reiterated its 'outperform' rating on the stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
Edwards Lifesciences
American medical technology company
-
Royal Bank of Canada
financial institution in Canada
Related events
- TD Cowen issued a buy rating and price target for Evolv Technologies Holdings, Inc.
- TD Cowen increased its target price and issued a buy rating for Butterfly Network, with MarketBeat aggregating the data.
- Truist Financial boosted price target and gave buy rating, and TD Cowen lifted target price and gave buy rating for Encompass Health.
- Jefferies Financial Group boosted its price target and gave a buy rating, while TD Cowen started coverage and issued a buy rating for Voyager Technologies, Inc.
- TD Cowen maintained a Buy rating on Forgent on September 15, 2026.